With the explosive growth in the generic drug market, generic companies (like yours) are in a battle to claim a share of the soon-to-be-expired drugs as quickly as possible. You would want to know as much as possible, and keeping that very thought in mind, we collated a list of 54 drugs that are going off-patent in 2024. We also included other information like yearly sales, dosage information, ingredients, and the diseases they cure. This could help you easily choose the most profitable drug to develop a generic version of.
Loved the idea and the list? Thank us later in the comments section. Now onto the list.
The article has a list of drug patents expiring in 2024. You can get the drug patents expiration list from 2026 to 2030 in a PDF by filling out the form below.
[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][mk_fancy_title color=”#2878bf” size=”32″ line_height=”80″ font_weight=”bolder” txt_transform=”uppercase” margin_bottom=”0″ font_family=”none”]Drug Patents Expiring in 2024[/mk_fancy_title][mk_divider margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Mulpleta
Lusutrombopag[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
200 Million Yen (2018)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7601746 | September 05, 2024 |
| US8889722 | July 29, 2028 |
| US8530668 | January 21, 2030 |
[/mk_table][vc_column_text css=”.vc_custom_1652960902187{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Shionogi Inc.
Ingredients: LUSUTROMBOPAG
Treatment: Thrombocytopenia[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Invokamet XR
Canagliflozin; Metformin Hydrochloride[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$1.41 Billion (2016)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8785403 | July 30, 2024 |
| US8222219 | March 11, 2025 |
[/mk_table][vc_column_text css=”.vc_custom_1614606440968{margin-bottom: 0px !important;}”]Dosage: Tablet, Extended Release; Oral
Company: Janssen Pharmaceuticals Inc
Ingredients: Canagliflozin; Metformin Hydrochloride
Treatment: Type 2 Diabetes Mellitus[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Revlimid
Lenalidomide[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$10.82 Billion (2019)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7855217 | November 24, 2024 |
| US7465800 | April 27, 2027 |
[/mk_table][vc_column_text css=”.vc_custom_1652961069428{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Celgene Corp
Ingredients: LENALIDOMIDE
Treatment: Multiple Myeloma and Myelodysplastic Syndromes[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Rydapt
Midostaurin[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$150 Million (2018)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7973031 | October 17, 2024 |
| US8222244 | October 29, 2022 |
[/mk_table][vc_column_text css=”.vc_custom_1614607121225{margin-bottom: 0px !important;}”]Dosage: Capsule; Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: Midostaurin
Treatment: Acute Myeloid Leukemia[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Prevymis
Letermovir[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$370 Million (2020)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7196086 | May 22, 2024 |
| US8513255 | May 22, 2024 |
[/mk_table][vc_column_text css=”.vc_custom_1614607298036{margin-bottom: 0px !important;}”]Dosage: Solution; Intravenous
Company: Merck Sharp And Dohme Corp
Ingredients: Letermovir
Treatment: Cytomegalovirus (CMV) infection[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Vyndaqel
Tafamidis Meglumine[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$259 Million (Jan-Sep 2019)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7214695 | April 27, 2024 |
| US7214696 | December 19, 2023 |
| US8168663 | December 19, 2023 |
| US8653119 | January 28, 2024 |
[/mk_table][vc_column_text css=”.vc_custom_1614607395247{margin-bottom: 0px !important;}”]Dosage: Capsule; Oral
Company: Foldrx Pharmaceuticals Inc Sub Pfizer Inc
Ingredients: Tafamidis Meglumine
Treatment: Transthyretin Amyloid Polyneuropathy[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Lynparza
Olaparib[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$847 Million (2018)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7151102 | April 29, 2022 |
| US7449464 | October 11, 2024 |
| US7981889 | October 11, 2024 |
| US8912187 | March 12, 2024 |
[/mk_table][vc_column_text css=”.vc_custom_1614607546348{margin-bottom: 0px !important;}”]Dosage: Capsule; Oral
Company: AstraZeneca Pharmaceuticals LP
Ingredients: Olaparib
Treatment: Advanced Ovarian Cancer, Fallopian Tube Cancer[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Tasigna
Nilotinib[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$1.88 Billion (2019)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7169791 | January 04, 2024 |
| US8415363 | January 18, 2027 |
| US8163904 | February 23, 2029 |
| US9061029 | October 7, 2032 |
[/mk_table][vc_column_text css=”.vc_custom_1614607666680{margin-bottom: 0px !important;}”]Dosage: Capsule; Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: Nilotinib Hydrochloride
Treatment: Chronic Myelogenous Leukemia[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Xopenex HFA
Levalbuterol Tartrate[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$148 Million (2012)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7256310 | October 08, 2024 |
[/mk_table][vc_column_text css=”.vc_custom_1652960994702{margin-bottom: 0px !important;}”]Dosage: Aerosol, Metered; Inhalation
Company: Sunovion Pharmaceuticals Inc
Ingredients: Levalbuterol Tartrate
Treatment: Asthma and Chronic Obstructive Pulmonary Disease (COPD)[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Vandazole
Metronidazole[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7456207 | September 22, 2024 |
[/mk_table][vc_column_text css=”.vc_custom_1614607850728{margin-bottom: 0px !important;}”]Dosage: Gel; Vaginal
Company: Teva Pharmaceuticals USA
Ingredients: Metronidazole
Treatment: Bacterial Vaginosis[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Prialt
Ziconotide Acetate[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$27 Million (2017)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8653033 | October 10, 2024 |
| US8765680 | October 10, 2024 |
| US9707270 | October 10, 2024 |
[/mk_table][vc_column_text css=”.vc_custom_1614607959671{margin-bottom: 0px !important;}”]Dosage: Injectable; Intrathecal
Company: TerSera Therapeutics LLC
Ingredients: Ziconotide Acetate
Treatment: Pain Reliever[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Aloxi
Palonosetron Hydrochloride[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$400 Million (2019)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7947724 | January 30, 2024 |
| US7947725 | January 30, 2024 |
| US7960424 | January 30, 2024 |
| US8518981 | January 30, 2024 |
| US8598218 | January 30, 2024 |
| US9173942 | January 30, 2024 |
| US9439854 | January 30, 2024 |
| US9457020 | January 30, 2024 |
[/mk_table][vc_column_text css=”.vc_custom_1614608040549{margin-bottom: 0px !important;}”]Dosage: Injectable; Intravenous
Company: Helsinn Healthcare SA
Ingredients: Palonosetron Hydrochloride
Treatment: Acute Nausea and Vomiting[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Dificid
Fidaxomicin[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$60 Million (2021)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8586551 | January 23, 2024 |
| US7378508 | January 31, 2028 |
| US7863249 | January 31, 2028 |
[/mk_table][vc_column_text css=”.vc_custom_1652892572204{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Merck Sharp & Dohme Corp
Ingredients: FIDAXOMICIN
Treatment: Clostridioides difficile-associated Diarrhea (CDAD)[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Linzess
Linaclotide[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$287 Million (2021)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7371727 | January 28, 2024 |
| US7745409 | January 28, 2024 |
| US8080526 | January 28, 2024 |
| US7704947 | January 28, 2024 |
| US7304036 | August 30, 2026 |
[/mk_table][vc_column_text css=”.vc_custom_1652892728623{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Allergan
Ingredients: LINACLOTIDE
Treatment: Irritable Bowel Syndrome[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row]
[vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Myfembree
Relugolix/estradiol/norethisterone acetate[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7300935 | January 28, 2024 |
| US8058280 | January 28, 2024 |
[/mk_table][vc_column_text css=”.vc_custom_1652892861936{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Myovant Sciences
Ingredients: ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX
Treatment: Heavy Menstrual Bleeding[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Ferric Citrate
Ferric Citrate[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US9328133 | February 18, 2024 |
| US9757416 | February 18, 2024 |
| US8338642 | February 18, 2024 |
| US7767851 | February 18, 2024 |
[/mk_table][vc_column_text css=”.vc_custom_1652893019297{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Akebia Therapeutics
Ingredients: FERRIC CITRATE
Treatment: Hyperphosphataemia and Iron Deficiency Anaemia[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Ofev/Vargatef
Nintedanib[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7119093 | February 21, 2024 |
| US6762180 | October 1, 2025 |
[/mk_table][vc_column_text css=”.vc_custom_1652893184395{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Boehringer Ingelheim
Ingredients: NINTEDANIB ESYLATE
Treatment: Idiopathic Pulmonary Fibrosis[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Isentress
Raltegravir[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$857 Million (2020)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7119093 | February 21, 2024 |
| US6762180 | October 1, 2025 |
[/mk_table][vc_column_text css=”.vc_custom_1652893325524{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Merck Sharp & Dohme Corp
Ingredients: RALTEGRAVIR POTASSIUM
Treatment: HIV/AIDS[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Zontivity
Vorapaxar[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7304078 | April 6, 2024 |
| US7713999 | May 30, 2024 |
[/mk_table][vc_column_text css=”.vc_custom_1652893438652{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Merck Sharp & Dohme Corp
Ingredients: VORAPAXAR SULFATE
Treatment: Peripheral Arterial Disease[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Bosulif
Bosutinib[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$23 Million (2020)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| USRE42376 | April 13, 2024 |
| US7767678 | November 23, 2026 |
[/mk_table][vc_column_text css=”.vc_custom_1652893572116{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Pfizer
Ingredients: BOSUTINIB MONOHYDRATE
Treatment: Chronic Myelogenous Leukemia[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Omontys
Peginesatide[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7084245 | May 12, 2024 |
| US7414105 | May 12, 2024 |
| US7919118 | May 12, 2024 |
| US7528104 | May 12, 2024 |
[/mk_table][vc_column_text css=”.vc_custom_1652893865609{margin-bottom: 0px !important;}”]Dosage: Subcutaneous, intravenous
Company: Affymax Inc.
Ingredients: PEGINESATIDE ACETATE
Treatment: Anemia[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Aliqopa
Copanlisib[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7511041 | May 13, 2024 |
| USRE46856 | October 22, 2029 |
| US10383876 | March 29, 2032 |
[/mk_table][vc_column_text css=”.vc_custom_1652893982935{margin-bottom: 0px !important;}”]Dosage: Intravenous infusion
Company: Bayer
Ingredients: COPANLISIB DIHYDROCHLORIDE
Treatment: Relapsed follicular lymphoma[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Mayzent
Siponimod[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7939519 | May 19, 2024 |
[/mk_table][vc_column_text css=”.vc_custom_1652894088589{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Novartis
Ingredients: SIPONIMOD FUMARIC ACID
Treatment: Multiple Sclerosis[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Prevymis
Letermovir[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$281 Million (2020)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8513255 | May 22, 2024 |
| USRE46791 | May 22, 2024 |
[/mk_table][vc_column_text css=”.vc_custom_1652894211576{margin-bottom: 0px !important;}”]Dosage: Oral, Intravenous
Company: Merck & Co
Ingredients: LETERMOVIR
Treatment: Cytomegalovirus[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Xifaxan
Rifaximin[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7612199 | June 19, 2024 |
| US8835452 | June 19, 2024 |
| US8158781 | June 19, 2024 |
| US7045620 | June 19, 2024 |
| US7902206 | June 19, 2024 |
| US7906542 | June 1, 2025 |
| US8741904 | February 27, 2026 |
| US8193196 | September 2, 2027 |
[/mk_table][vc_column_text css=”.vc_custom_1652895090357{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Salix Pharmaceuticals
Ingredients: RIFAXIMIN
Treatment: Travelers’ Diarrhea, Irritable Bowel Syndrome[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Remodulin/Orenitram/Tyvaso
Treprostinil[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US9050311 | May 24, 2024 |
| US7417070 | July 30, 2026 |
| US8497393 | December 15, 2028 |
[/mk_table][vc_column_text css=”.vc_custom_1652894360388{margin-bottom: 0px !important;}”]Dosage: Subcutaneous, intravenous, inhalation, Oral
Company: United Therapeutics
Ingredients: TREPROSTINIL DIOLAMINE
Treatment: Pulmonary arterial hypertension[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Tpoxx
Tecovirimat[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8124643 | June 18, 2024 |
| US9339466 | March 23, 2031 |
[/mk_table][vc_column_text css=”.vc_custom_1652894479626{margin-bottom: 0px !important;}”]Dosage: Oral
Company: SIGA Technologies
Ingredients: TECOVIRIMAT
Treatment: Orthopoxviruses (Smallpox and Monkeypox)[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Nuvigil
Armodafinil[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7132570 | June 18, 2024 |
[/mk_table][vc_column_text css=”.vc_custom_1652894588446{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Teva Pharmaceuticals
Ingredients: ARMODAFINIL
Treatment: Excessive Daytime Sleepiness[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row]
[vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Oriahnn
Elagolix/estradiol/norethindrone acetate[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$145 Million (2021)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7419983 | July 6, 2024 |
| US7056927 | September 10, 2024 |
[/mk_table][vc_column_text css=”.vc_custom_1652946203839{margin-bottom: 0px !important;}”]Dosage: Oral
Company: AbbVie Inc.
Ingredients: ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE
Treatment: Heavy Menstrual Bleeding[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Xeglyze
Abametapir[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US9839631 | July 16, 2024 |
[/mk_table][vc_column_text css=”.vc_custom_1652946309031{margin-bottom: 0px !important;}”]Dosage: Topical
Company: Dr. Reddy’s Laboratories
Ingredients: ABAMETAPIR
Treatment: Head Lice Infestation[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Ninlaro
Ixazomib[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8546608 | August 12, 2024 |
| US8003819 | August 6, 2027 |
| US8530694 | August 6, 2027 |
| US7687662 | August 6, 2027 |
| US8859504 | June 16, 2029 |
| US7442830 | November 20, 2029 |
[/mk_table][vc_column_text css=”.vc_custom_1652946604909{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Takeda
Ingredients: IXAZOMIB CITRATE
Treatment: Multiple Myeloma[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Prezista
Darunavir[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8518987 | August 16, 2024 |
| US7700645 | June 26, 2027 |
[/mk_table][vc_column_text css=”.vc_custom_1652947786133{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Janssen Therapeutics
Ingredients: DARUNAVIR
Treatment: HIV/AIDS[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Xarelto
Rivaroxaban[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7157456 | August 28, 2024 |
[/mk_table][vc_column_text css=”.vc_custom_1652947866042{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Janssen Therapeutics
Ingredients: RIVAROXABAN
Treatment: Blood clots[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]MoviPrep
POLYETHYLENE GLYCOL 3350[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7169381 | September 1, 2024 |
| US7658914 | September 1, 2024 |
[/mk_table][vc_column_text css=”.vc_custom_1652947989991{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Velinor A.G
Ingredients: ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE
Treatment: Use for Colonoscopy Bowel Preparation[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Aldara
Imiquimod[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7696159 | October 1, 2024 |
[/mk_table][vc_column_text css=”.vc_custom_1652948130015{margin-bottom: 0px !important;}”]Dosage: Topical
Company: 3M Pharmaceutical
Ingredients: IMIQUIMOD
Treatment: Genital Warts, Superficial Basal cell carcinoma, and Actinic Keratosis[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Brilinta
Ticagrelor[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$1.4 Billion (2021)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| USRE46276 | October 30, 2024 |
[/mk_table][vc_column_text css=”.vc_custom_1652948254988{margin-bottom: 0px !important;}”]Dosage: Oral
Company: AstraZeneca
Ingredients: TICAGRELOR
Treatment: Stroke, Heart Attack[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Xiidra
Lifitegrast[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7745460 | November 5, 2024 |
| US7928122 | November 5, 2024 |
| US7314938 | March 10, 2025 |
| US8084047 | May 17, 2026 |
| US9890141 | October 21, 2030 |
[/mk_table][vc_column_text css=”.vc_custom_1652948610020{margin-bottom: 0px !important;}”]Dosage: Eye Drops
Company: Novartis
Ingredients: LIFITEGRAST
Treatment: Signs and Symptoms of Dry Eye[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Nourianz
Istradefylline[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7541363 | November 13, 2024 |
[/mk_table][vc_column_text css=”.vc_custom_1652960192000{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Kyowa Kirin Co.
Ingredients: ISTRADEFYLLINE
Treatment: Levodopa/Carbidopa in adults with Parkinson’s disease[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Ponvory
Ponesimod[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| USRE43728 | November 16, 2024 |
| US9062014 | May 6, 2032 |
[/mk_table][vc_column_text css=”.vc_custom_1652960295056{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Janssen Pharmaceuticals
Ingredients: PONESIMOD
Treatment: Multiple Sclerosis [/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Tukysa
Tucatinib[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7452895 | November 16, 2024 |
| US8648087 | April 12, 2031 |
[/mk_table][vc_column_text css=”.vc_custom_1652960380071{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Seagen Inc
Ingredients: TUCATINIB
Treatment: HER2-positive Breast Cancer [/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Asclera/Aethoxysklerol/Varithena
Polidocanol[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7731986 | November 17, 2024 |
[/mk_table][vc_column_text css=”.vc_custom_1652960487331{margin-bottom: 0px !important;}”]Dosage: Topical, Subcutaneous Injection
Company: Methapharm, Inc.
Ingredients: POLIDOCANOL
Treatment: Itching caused by Eczema and Dry Skin[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Zepzelca
Lurbinectedin[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7763615 | December 13, 2024 |
[/mk_table][vc_column_text css=”.vc_custom_1652960592349{margin-bottom: 0px !important;}”]Dosage: Intravenous Injection
Company: PharmaMar, S.A.
Ingredients: LURBINECTEDIN
Treatment: Metastatic Small Cell Lung Cancer (SCLC)[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Victrelis
Boceprevir[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| USRE43298 | December 22, 2024 |
[/mk_table][vc_column_text css=”.vc_custom_1652960696328{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Merck & Co
Ingredients: BOCEPREVIR
Treatment: Hepatitis caused by Hepatitis C virus (HCV) genotype 1[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_column_text css=”.vc_custom_1615816365701{margin-bottom: 0px !important;}”]Conclusion
As a drug patent expires it expands the gateway for a number of competitors to enter the market. Tracking these patent expirations beforehand can not only help evaluate business opportunities but also help in refining market entry strategies. But there still lies legal as well as technology threats and hurdles that a generic company will face depending on the drug they choose for the generic version.
With proper research and threat analysis, developing a generic version wouldn’t be as terrifying. How to go about it? Well, let’s start with getting in touch by filling the form below and we’ll get back to you in no time.
Authored by: Divya Goyal, Team Lead, Life Science Team, and Madan Ekhande, Research Analyst, Life Science Team[/vc_column_text][/vc_column][/vc_row]
